Systems, compositions, and methods for discovery of MSI and neoepitopes that predict sensitivity to checkpoint inhibitors
Systems and methods are presented that allow for predicting treatment response of a tumor to a checkpoint inhibitor. In one exemplary aspect, the treatment response is directly associated with a relatively high number of patient- and tumor-specific immunologically visible neoepitopes. Specific mutational patterns in the nucleic acid encoding the neoepitope may be further indicative of treatment response.
1. A method of treating a patient having a cancer using immunotherapy, the method comprising:
comparing genomic sequences of tumor tissue from the patient and a matched normal tissue from the patient to identify at least 50 missense mutation based patient-specific and tumor-specific neoepitopes that have a binding affinity to an HLA type of the patient and
administering a treatment comprising an effective amount of a checkpoint inhibitor to the patient:
wherein the at least 50 neoepitopes each have a binding affinity of less than 500 nM; and
wherein the neoepitopes are peptides having a length of 5 to 30 amino acids.
2. The method of claim 1 wherein theplurality of missense mutations have been selected from each of the neoepitopes using a plurality of distinct individual neoepitope sequences in which a changed amino acid has a distinct position within the neoepitope sequence.
3. The method of claim 2 wherein the individual neoepitope sequences have a length of between 7 and 20 amino acids.
4. The method of claim 1 wherein the missense mutations are filtered by at least one of an a priori known molecular variation selected from the group consisting of a single nucleotide polymorphism, a short deletion and insertion polymorphism, a microsatellite marker, a short tandem repeat, a heterozygous sequence, a multinucleotide polymorphism, and a named variant.
5. The method of claim 1 wherein the high-affinity HLA-matched neoepitopes have been identified by determining affinity of the neoepitopes to at least one MHC Class I sub-type and to at least one MHC Class II sub-type of the patient.
6. The method of claim 5 , further comprising a determination of expression level of the neoepitopes.
7. The method of claim 1 wherein the high-affinity HLA-matched neoepitopes have an affinity to at least one MHC Class I sub-type or to at least one MHC Class II sub-type of the patient of equal or less than 150 nM.
8. The method of claim 1 further comprising a step of filtering the HLA-matched neoepitopes by a mutation signature.
9. The method of claim 8 wherein the mutation signature is a signature characteristic for UV-induced DNA damage or smoking-induced DNA damage.
10. The method of claim 1 , wherein at least 100 HLA-matched neoepitopes each have the binding affinity of less than 500 nM.
11. The method of claim 10 wherein the at least 100 HLA-matched neoepitopes have an affinity to at least one MHC Class I sub-type or to at least one MHC Class II sub-type of the patient of equal or less than 150 nM.
12. The method of claim 1 further comprising a step of determining microsatellite instability (MSI) in the diseased tissue.
13. The method of claim 1 further comprising a step of determining defective mismatch repair (MMR) in the diseased tissue.
14. The method of claim 1 wherein the checkpoint inhibitor is a CTLA-4 inhibitor or a PD-1 inhibitor.